BR112015030723A2 - compostos de tetra-hidrocarbazol e carbazol carboxamida substituídos úteis como inibidores da quinase - Google Patents

compostos de tetra-hidrocarbazol e carbazol carboxamida substituídos úteis como inibidores da quinase

Info

Publication number
BR112015030723A2
BR112015030723A2 BR112015030723A BR112015030723A BR112015030723A2 BR 112015030723 A2 BR112015030723 A2 BR 112015030723A2 BR 112015030723 A BR112015030723 A BR 112015030723A BR 112015030723 A BR112015030723 A BR 112015030723A BR 112015030723 A2 BR112015030723 A2 BR 112015030723A2
Authority
BR
Brazil
Prior art keywords
compounds
kinase inhibitors
compounds useful
carboxamide compounds
carbazole carboxamide
Prior art date
Application number
BR112015030723A
Other languages
English (en)
Other versions
BR112015030723A8 (pt
Inventor
S Srivastava Anurag
M Langevine Charles
G Batt Douglas
V Delucca George
A Tino Joseph
Beaudoin Bertrand Myra
Shi Qing
Liu Qingjie
Hunter Watterson Scott
Sung Ko Soo
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR112015030723A2 publication Critical patent/BR112015030723A2/pt
Publication of BR112015030723A8 publication Critical patent/BR112015030723A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

resumo patente de invenção: "compostos de tetra-hidrocarbazol e carbazol carboxamida substituídos úteis como inibidores da quinase". são divulgados compostos de fórmula (i) (i) em que: as duas linhas tracejadas representam duas ligações individuais ou duas ligações duplas; q é: r1 é f, cl, -cn, ou -ch3; r2 é cl ou -ch3; r3 é -c(ch3)2oh ou -ch2ch2oh; ra é h ou -ch3; cada r6 é independentemente f, cl, -ch3, e/ou -och3; e n é zero, 1, ou 2. também divulgados são os métodos de uso de tais compostos como inibidores da tirosina quinase de bruton (btk), e as composições farmacêuticas compreendendo tais compostos. estes compostos são úteis no tratamento, na prevenção ou no retardo da progressão de doenças ou distúrbios em uma variedade de áreas terapêuticas, tais como as doenças autoimunes e as doenças vasculares. 1/1
BR112015030723A 2013-06-25 2014-06-25 compostos de tetra-hidrocarbazol e carbazol carboxamida substituídos úteis como inibidores da quinase, seu uso e composição farmacêutica BR112015030723A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361839141P 2013-06-25 2013-06-25
PCT/US2014/043978 WO2014210085A1 (en) 2013-06-25 2014-06-25 Substituted tetrahydrocarbazole and carbazole carboxamide compounds useful as kinase inhibitors

Publications (2)

Publication Number Publication Date
BR112015030723A2 true BR112015030723A2 (pt) 2017-07-25
BR112015030723A8 BR112015030723A8 (pt) 2020-01-07

Family

ID=51210830

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015030723A BR112015030723A8 (pt) 2013-06-25 2014-06-25 compostos de tetra-hidrocarbazol e carbazol carboxamida substituídos úteis como inibidores da quinase, seu uso e composição farmacêutica

Country Status (31)

Country Link
US (6) US9334290B2 (pt)
EP (1) EP3013814B1 (pt)
JP (1) JP6353529B2 (pt)
KR (1) KR102346508B1 (pt)
CN (1) CN105358546B (pt)
AR (1) AR096721A1 (pt)
AU (1) AU2014302548B2 (pt)
BR (1) BR112015030723A8 (pt)
CA (1) CA2916500A1 (pt)
CL (1) CL2015003635A1 (pt)
CY (1) CY1119371T1 (pt)
DK (1) DK3013814T3 (pt)
EA (1) EA026729B1 (pt)
ES (1) ES2636652T3 (pt)
HK (1) HK1223359A1 (pt)
HR (1) HRP20171031T1 (pt)
HU (1) HUE034460T2 (pt)
IL (1) IL243296B (pt)
LT (1) LT3013814T (pt)
MA (1) MA38648B1 (pt)
MY (1) MY176631A (pt)
PE (1) PE20160519A1 (pt)
PH (1) PH12015502630A1 (pt)
PL (1) PL3013814T3 (pt)
PT (1) PT3013814T (pt)
RS (1) RS56371B1 (pt)
SI (1) SI3013814T1 (pt)
TN (1) TN2015000529A1 (pt)
TW (1) TWI648272B (pt)
UY (1) UY35625A (pt)
WO (1) WO2014210085A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201510028PA (en) 2013-06-25 2016-01-28 Bristol Myers Squibb Co Carbazole carboxamide compounds useful as kinase inhibitors
KR102514914B1 (ko) * 2014-10-24 2023-03-27 브리스톨-마이어스 스큅 컴퍼니 카르바졸 유도체
AR102426A1 (es) 2014-10-24 2017-03-01 Bristol Myers Squibb Co Compuestos de indolcarboxamida como inhibidores de btk
CN107108555B (zh) 2014-10-24 2020-12-01 百时美施贵宝公司 三环阻转异构体化合物
CA3029482A1 (en) 2016-07-01 2018-01-04 Brio Device Llc Intubation stylet with video feed
CN108101905A (zh) * 2016-11-24 2018-06-01 中国科学院上海药物研究所 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
CN110545826A (zh) 2016-12-03 2019-12-06 朱诺治疗学股份有限公司 用于与激酶抑制剂组合使用治疗性t细胞的方法和组合物
JP7028889B2 (ja) * 2016-12-20 2022-03-02 ブリストル－マイヤーズ スクイブ カンパニー テトラヒドロカルバゾールカルボキサミド化合物の製造方法
WO2019208805A1 (ja) 2018-04-27 2019-10-31 小野薬品工業株式会社 Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤
CA3108065A1 (en) 2018-07-31 2020-02-06 Loxo Oncology, Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
WO2022212893A1 (en) 2021-04-02 2022-10-06 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
WO2023156311A1 (en) * 2022-02-15 2023-08-24 F. Hoffmann-La Roche Ag Processes for the preparation of 1,2,3,5,6,7-hexahydro-s-indacene derivatives

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
CA2140722A1 (en) 1994-01-24 1995-07-25 Joseph A. Jakubowski Beta-carboline thromboxane synthase inhibitors
WO2005014599A1 (en) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
WO2005005429A1 (en) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
US20050288295A1 (en) 2003-11-11 2005-12-29 Currie Kevin S Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
WO2006044687A2 (en) 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
MX2007005643A (es) 2004-11-10 2008-03-13 Cgi Pharmaceuticals Inc Ciertas imidazo [1,2-a] pirazin-8-ilaminas, metodo para su elaboracion y metodo de uso de las mismas.
MX2007007345A (es) 2004-12-17 2007-09-07 Glenmark Pharmaceuticals Sa Compuestos heterociclicos novedosos utiles para el tratamiento de trastornos inflamatorios y alergicos.
TW200716551A (en) 2005-03-10 2007-05-01 Cgi Pharmaceuticals Inc Certain substituted amides, method of making, and method of use thereof
JP2009508872A (ja) 2005-09-16 2009-03-05 セレネックス， インコーポレイテッド カルバゾール誘導体
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
CA2630562C (en) 2005-11-22 2013-12-31 Merck & Co., Inc. Tricyclic compounds useful as inhibitors of kinases
US20100160292A1 (en) 2006-09-11 2010-06-24 Cgi Pharmaceuticals, Inc Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors
WO2008032171A1 (en) 2006-09-11 2008-03-20 Matrix Laboratories Ltd. Dibenzofuran derivatives as inhibitors of pde-4 and pde-10
US20090062251A1 (en) 2007-08-17 2009-03-05 Astrazeneca Ab Novel Compounds 002
AU2008335761B2 (en) 2007-12-13 2014-04-24 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
PL2247558T3 (pl) 2008-02-14 2022-05-02 Eli Lilly And Company Nowe środki obrazujące do wykrywania czynnościowych zaburzeń neurologicznych
GB0809360D0 (en) 2008-05-22 2008-07-02 Isis Innovation Calcium modulation
EP2151441A1 (en) 2008-08-06 2010-02-10 Julius-Maximilians-Universität Würzburg Beta-carbolin-derivates as substrates for an enzyme
JP5487214B2 (ja) * 2008-12-19 2014-05-07 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ阻害剤として有用なカルバゾールカルボキシアミド化合物
CN101475571B (zh) 2009-01-21 2011-06-22 中国药科大学 β-咔啉类细胞周期蛋白依赖性激酶2抑制剂及其用途
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
AU2011232058B2 (en) 2010-03-26 2016-09-08 Merck Patent Gmbh Benzonaphthyridinamines as autotaxin inhibitors
EP2582668B1 (en) * 2010-06-16 2016-01-13 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
EP2455378A1 (en) 2010-11-03 2012-05-23 Philip Morris Products S.A. Carbazole and carboline derivatives, and preparation and therapeutic applications thereof
BR112013011991A2 (pt) 2010-11-15 2016-08-30 Viiv Healthcare Uk Ltd composto, composição farmacêutica, uso de um composto, método de tratamento, produto, e kit.
CN103582637B (zh) 2011-05-17 2015-08-12 弗·哈夫曼-拉罗切有限公司 酪氨酸激酶抑制剂
WO2013054185A1 (en) 2011-10-13 2013-04-18 Pfizer, Inc. Pyrimidine and pyridine derivatives useful in therapy

Also Published As

Publication number Publication date
BR112015030723A8 (pt) 2020-01-07
TW201536774A (zh) 2015-10-01
US20140378475A1 (en) 2014-12-25
KR20160022889A (ko) 2016-03-02
CN105358546B (zh) 2017-10-31
TWI648272B (zh) 2019-01-21
US20190382416A1 (en) 2019-12-19
HK1223359A1 (zh) 2017-07-28
MA38648B1 (fr) 2018-06-29
US10106559B2 (en) 2018-10-23
MY176631A (en) 2020-08-19
PE20160519A1 (es) 2016-05-21
EP3013814B1 (en) 2017-06-14
CL2015003635A1 (es) 2016-07-29
WO2014210085A9 (en) 2015-12-23
US9334290B2 (en) 2016-05-10
PH12015502630A1 (en) 2016-03-07
MA38648A1 (fr) 2017-09-29
AU2014302548B2 (en) 2018-05-10
AU2014302548A1 (en) 2016-02-11
ES2636652T3 (es) 2017-10-06
KR102346508B1 (ko) 2022-01-03
RS56371B1 (sr) 2017-12-29
PL3013814T3 (pl) 2017-11-30
EA026729B1 (ru) 2017-05-31
US9850258B2 (en) 2017-12-26
UY35625A (es) 2014-12-31
HRP20171031T1 (hr) 2017-10-06
SI3013814T1 (sl) 2017-08-31
TN2015000529A1 (en) 2017-04-06
US20180079758A1 (en) 2018-03-22
JP6353529B2 (ja) 2018-07-04
PT3013814T (pt) 2017-08-10
LT3013814T (lt) 2017-08-10
EP3013814A1 (en) 2016-05-04
IL243296B (en) 2018-05-31
DK3013814T3 (en) 2017-09-25
WO2014210085A1 (en) 2014-12-31
CA2916500A1 (en) 2014-12-31
EA201592287A1 (ru) 2016-06-30
US20160194338A1 (en) 2016-07-07
AR096721A1 (es) 2016-01-27
HUE034460T2 (en) 2018-02-28
CY1119371T1 (el) 2018-02-14
CN105358546A (zh) 2016-02-24
US20170283438A1 (en) 2017-10-05
JP2016523907A (ja) 2016-08-12
US10435415B2 (en) 2019-10-08
US20190023719A1 (en) 2019-01-24

Similar Documents

Publication Publication Date Title
BR112015030723A2 (pt) compostos de tetra-hidrocarbazol e carbazol carboxamida substituídos úteis como inibidores da quinase
PH12020500265A1 (en) Indole carboxamides compounds useful as kinase inhibitors
BR112015031432A2 (pt) compostos de carbazol carboxamida úteis como inibidores de cinase
EA201992878A1 (ru) Соединения для лечения болезни хантингтона
BR112015020389A8 (pt) compostos carbazol úteis como inibidores de bromodomínio, seu uso, bem como composição e produto farmacêuticos compreendendo os mesmos
EA201490300A1 (ru) 4-имидазопиридазин-1-ил-бензамиды и 4-имидазотриазин-1-ил-бензамиды в качестве btk-ингибиторов
EA202191050A1 (ru) Ингибиторы pfkfb3 и их использование
EA201790745A1 (ru) Трициклические соединения
EA201790870A1 (ru) Трициклические атропоизомерные соединения
EA201690645A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ 1-(4-ПИРИМИДИНИЛ)-1H-ПИРРОЛО[3,2-c]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ NIK
EA202091020A1 (ru) Замещенные имидазопиридинамиды и их применение
EA201792341A1 (ru) Производные пиразола, пригодные в качестве ингибиторов белка, активирующего 5-липоксигеназу (flap)
EA202191103A1 (ru) Терапевтические соединения
EA202091047A1 (ru) Пиридинкарбонильные производные и их терапевтические применения в качестве ингибиторов trpc6
EA202092600A1 (ru) Тетрациклические гетероарильные соединения
EA201990943A1 (ru) 6,7,8,9-ТЕТРАГИДРО-3H-ПИРАЗОЛО[4,3-f]ИЗОХИНОЛИНОВЫЕ ПРОИЗВОДНЫЕ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ РАКА
EA201990261A1 (ru) 2,5-двузамещенные 3-метилпиразины и 2,5,6-тризамещенные 3-метилпиразины в качестве аллостерических ингибиторов shp2
AR105921A1 (es) Compuestos terapéuticos para el dolor y síntesis de estos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]